S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Fund/Baker Bros Advisors/Q4 2023

Baker Bros Advisors

Periodo: Q4 2023 · Depositato: 2024-02-14
Vedi su SEC EDGAR
AUM
$8.79B
Valore totale del portafoglio
Posizioni
84
Titoli dichiarati
Prima Posizione
INCY
25.9% $2.27B
Var. Trimestrali
+5 / -8
nuovi · usciti
⚠️Informativa sui Depositi 13F

I dati AUM mostrati sono calcolati sommando il valore di mercato dichiarato di tutte le posizioni nei depositi SEC 13F-HR — non rappresentano il patrimonio effettivo gestito dal fondo.

  • Escluse liquidità, obbligazioni, private equity, posizioni corte e azioni estere non soggette all'obbligo di dichiarazione.
  • Per le opzioni PUT e CALL, il Valore dichiarato è il valore nozionale delle azioni sottostanti — non il premio pagato. Ciò sovrastima significativamente il capitale effettivamente a rischio.
  • Il patrimonio reale del fondo è tipicamente superiore e include strategie, strumenti e posizioni che non compaiono mai in un 13F.
  • I depositi 13F riguardano i gestori istituzionali con ≥$100M in titoli 13F. Le posizioni riflettono le partecipazioni a fine trimestre, divulgate entro 45 giorni dalla fine del periodo.

Dati provenienti da SEC EDGAR. Questo tracker è a scopo puramente informativo e non costituisce consulenza finanziaria.

Partecipazioni in Portafoglio

Prime 30 posizioni

⚠️ Performance % calcolata dalla data di deposito ( 2024-02-14) si riferisce al titolo sottostante — non al P&L del derivato.
TickerEmittenteNozionalePortafoglio %Al DepositoOra (Fine Giornata)Dal DepositoAllocazione
INCYIncyte Corporation$2.27B25.85%$65.45$116.86+78.5%
25.9%
ONCBeiGene, Ltd.$1.91B21.69%$177.00$297.65+68.2%
21.7%
ACADACADIA Pharmaceuticals Inc.$1.34B15.27%$30.86$25.97-15.8%
15.3%
MDGLMadrigal Pharmaceuticals, Inc.$455.8M5.19%$226.86$528.10+132.8%
5.2%
RYTMRhythm Pharmaceuticals, Inc.$294.1M3.35%$45.13$114.17+153.0%
3.4%
MRTXMirati Therapeutics, Inc.$242.1M2.76%
2.8%
IMCRImmunocore Holdings plc$172.2M1.96%$71.64$32.50-54.6%
2.0%
KYMRKymera Therapeutics, Inc.$152.7M1.74%$25.35$113.51+347.8%
1.7%
RVMDRevolution Medicines, Inc.$147.7M1.68%$28.23$189.24+570.4%
1.7%
Invitae Corporation$131.2M1.49%
1.5%
ABCLAbCellera Biologics Inc.$130.8M1.49%$5.73$8.11+41.5%
1.5%
ROIVRoivant Sciences Ltd.$85.3M0.97%$11.35$35.13+209.5%
1.0%
REPLReplimune Group, Inc.$80.5M0.92%$8.67$11.58+33.6%
0.9%
TRDAEntrada Therapeutics, Inc.$73.4M0.84%$15.17$7.72-49.1%
0.8%
RAREUltragenyx Pharmaceutical Inc.$70.1M0.80%$48.17$33.47-30.5%
0.8%
CERECerevel Therapeutics Holdings, Inc.$67.8M0.77%
0.8%
IMTXImmatics N.V.$61.5M0.70%$10.72$9.95-7.2%
0.7%
BCRXBioCryst Pharmaceuticals, Inc.$60.7M0.69%$6.07$9.84+62.1%
0.7%
ARGXargenx SE$57.5M0.65%$381.00$939.68+146.6%
0.7%
DNLIDenali Therapeutics Inc.$56.0M0.64%$21.39$25.83+20.8%
0.6%
AKROAkero Therapeutics, Inc.$55.3M0.63%
0.6%
KODKodiak Sciences Inc.$52.6M0.60%$3.18$38.54+1112.0%
0.6%
KNSAKiniksa Pharmaceuticals, Ltd.$49.3M0.56%$18.53$64.53+248.3%
0.6%
XENEXenon Pharmaceuticals Inc.$45.8M0.52%$44.91$60.96+35.7%
0.5%
PRLDPrelude Therapeutics Inc.$43.2M0.49%$4.07$4.91+20.6%
0.5%
CERSCerus Corporation$42.1M0.48%$2.16$3.16+46.3%
0.5%
NRIXNurix Therapeutics, Inc.$40.1M0.46%$10.22$23.97+134.5%
0.5%
AVTEAerovate Therapeutics, Inc.$38.0M0.43%
0.4%
IDYAIDEAYA Biosciences, Inc.$37.8M0.43%$35.22$37.65+6.9%
0.4%
EWTXEdgewise Therapeutics, Inc.$34.0M0.39%$11.00$39.56+259.6%
0.4%

Attività Trimestre su Trimestre

Q4 2023 vs. Q3 2023

Nuove Posizioni (5)

TickerEmittenteNozionale
CERECerevel Therapeutics Holdings, Inc.$67.8M
CLDXCelldex Therapeutics, Inc.$9.8M
NGNENeurogene Inc.$8.8M
PFEPfizer Inc.$1.0M
TYRATyra Biosciences, Inc.$0.1M

Posizioni Chiuse (8)

TickerEmittenteNozionale
SGENSeagen Inc.$9.45B
BMRNBioMarin Pharmaceutical Inc.$337.1M
SWTXSpringWorks Therapeutics, Inc.$69.4M
COGTCogent Biosciences, Inc.$12.6M
PACBPacific Biosciences of California, Inc.$9.4M
HRTXHeron Therapeutics, Inc.$8.4M
ARVNArvinas, Inc.$8.1M
BLUEXXXXbluebird bio, Inc.$7.6M

Aumentate (8)

TickerEmittenteNozionaleVar. AzioniDal Deposito
SERASera Prognostics, Inc.$29.7M+258.6%
EWTXEdgewise Therapeutics, Inc.$28.0M+196.5%+259.6%
MRTXMirati Therapeutics, Inc.$180.7M+192.3%
BCYCBicycle Therapeutics plc$15.4M+112.2%
REPLReplimune Group, Inc.$2.1M+108.5%+33.6%
GRCLGracell Biotechnologies Inc.$18.0M+108.0%
XNCRXencor, Inc.$2.7M+99.3%
RVMDRevolution Medicines, Inc.$73.2M+91.3%+570.4%

Ridotte (8)

TickerEmittenteNozionaleVar. AzioniDal Deposito
CABACabaletta Bio, Inc.$-24.0M-99.2%
PRAXPraxis Precision Medicines, Inc.$-0.3M-93.0%
WHWKAadi Bioscience, Inc.$-4.3M-74.6%
BCELAtreca, Inc.$-0.6M-38.4%
ROIVRoivant Sciences Ltd.$-53.5M-36.1%+209.5%
IPSCCentury Therapeutics, Inc.$0.3M-30.6%
BCRXBioCryst Pharmaceuticals, Inc.$-29.3M-20.3%+62.1%
ACHLAchilles Therapeutics plc$-0.5M-17.8%
Torna agli Hedge Fund